Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Nurix Therapeutics Inc NRIX

Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecules and antibody therapies based on the modulation of cellular protein levels as a treatment approach for cancer, inflammatory conditions and other diseases. It DELigase is an integrated discovery platform, to identify and advance drug... see more

Recent & Breaking News (NDAQ:NRIX)

Nurix Therapeutics to Participate and Present at Upcoming Investor Conferences

GlobeNewswire March 9, 2021

Nurix Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

GlobeNewswire March 4, 2021

Nurix Therapeutics Announces Launch of Proposed Public Offering of Common Stock

GlobeNewswire March 2, 2021

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides a Corporate Update

GlobeNewswire February 16, 2021

Nurix Therapeutics Announces Expansion of its Strategic Collaboration with Sanofi to Develop Novel Targeted Protein Degradation Therapies

GlobeNewswire January 7, 2021

Nurix Therapeutics Announces Presentation at 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2021

Nurix Therapeutics Presents Preclinical Data at 62nd American Society of Hematology (ASH) Annual Meeting and Exposition

GlobeNewswire December 7, 2020

Nurix Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2020

Nurix Therapeutics to Present Preclinical Data at Upcoming 5th Medicinal Chemistry & Protein Degradation Summit and 62nd ASH Annual Meeting and Exposition

GlobeNewswire November 4, 2020

Nurix Therapeutics Announces Appointment of Robert Tjian as Chairman of Scientific Advisory Board and His Resignation from the Board of Directors

GlobeNewswire October 26, 2020

Nurix Therapeutics Reports Third Quarter Fiscal 2020 Financial Results and Provides a Corporate Update

GlobeNewswire October 14, 2020

Nurix Therapeutics to Present at 3rd Annual Targeted Protein Degradation Summit

GlobeNewswire October 6, 2020

Nurix Therapeutics Announces Pricing of $209 Million Initial Public Offering

GlobeNewswire July 23, 2020